logo
Kennedy's vaccine committee to vote on flu vaccines and controversial preservative

Kennedy's vaccine committee to vote on flu vaccines and controversial preservative

Yahoo26-06-2025
ATLANTA (AP) — U.S. Health Secretary Robert F. Kennedy's new vaccine advisory committee returned to work Thursday, and the panel may vote on proposals about fall flu vaccines and a preservative in some flu shots that antivaccine groups have falsely tied to autism.
The Advisory Committee on Immunization Practices, meeting in Atlanta, also is expected to vote on whether to recommend a second version of a lab-made antibody that protects newborns against a childhood menace called respiratory syncytial virus, or RSV.
The ACIP, created more than 60 years ago, helps the Centers for Disease Control and Prevention determine who should be vaccinated against a long list of diseases, and when. Those recommendations have a big impact on whether insurance covers vaccinations and where they're available.
Kennedy was a leading voice in the antivaccine movement before becoming the nation's top health official. He fired the previous 17-member panel this month and replaced it with a seven-member group that includes several vaccine skeptics.
At its June meetings, the committee usually refreshes guidance for Americans 6 months and older to get a flu shot, and helps propel the annual fall vaccination campaign.
Presentations prepared for Thursday's meeting suggest that the panel may do much the same this year. But there's also a flu-related vote that promises controversy.
It concerns thimerosal, a form of mercury that's been added to vaccines since the early 20th century to preventing bacterial contamination in multi-dose vials.
Kennedy has long held there was a tie between thimerosal and autism, and also accused the government of hiding the danger. Study after study has found no evidence that thimerosal causes autism. But since 2001, vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with limited exceptions.
Thimerosal was placed on the meeting agenda shortly after Kennedy's new vaccine advisory was named last week.
Before the vote, the committee will hear from Lyn Redwood, the former president of what is now known as Children's Health Defense — an antivaccine group founded by Kennedy.
Some public health experts contend the thimerosal discussion will unnecessarily raise doubt in vaccines while possibly also making them more expensive and harder to get this fall.
At the panel's meeting Wednesday, Chrissie Juliano, executive director of the Big Cities Health Coalition, lamented the ouster of the former ACIP panel and the agenda of the new one.
Her organization, which represents large city health departments, 'is deeply concerned that many routine vaccines may soon become inaccessible or unaffordable for millions of Americans if ACIP makes changes based on ideology rather than science," she said. "The stakes are simply too high to let that happen.'
___
Neergaard reported from Washington.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Asking Eric: Wife left a gift to niece in her will, but I hesitate to honor it
Asking Eric: Wife left a gift to niece in her will, but I hesitate to honor it

Washington Post

time42 minutes ago

  • Washington Post

Asking Eric: Wife left a gift to niece in her will, but I hesitate to honor it

Dear Eric: When my wife and I updated our wills, she designated a diamond tennis bracelet and diamond stud earrings to her niece (she had no biological children of her own). Later that month my wife was diagnosed with pancreatic cancer to which she would succumb 19 months later. My daughter (my wife's stepdaughter) is a radiation oncologist and became our daily advocate as we navigated the byzantine world of cancer treatment.

Sell HIMS Stock Ahead of Its Earnings?
Sell HIMS Stock Ahead of Its Earnings?

Forbes

timean hour ago

  • Forbes

Sell HIMS Stock Ahead of Its Earnings?

Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Yahoo

time2 hours ago

  • Yahoo

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store